Search Results

Filter
  • 1-10 of  477 results for ""PYRAZINES""
Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request
Academic Journal

Novel 2-phenoxypyrido[3,2- b ]pyrazin-3(4 H )-one derivatives as potent and selective aldose reductase inhibitors with antioxidant activity.

  • Authors : Hao X; a The State Key Laboratory of Medicinal Chemical Biology, Nankai University , Tianjin , PR China.; b Department of Applied Chemistry, Beijing Institute of Technology , Beijing , PR China.

Subjects: Drug Design*; Aldehyde Reductase/Aldehyde Reductase/Aldehyde Reductase/*antagonists & inhibitors ; Antioxidants/Antioxidants/Antioxidants/*pharmacology

  • Source: Journal of enzyme inhibition and medicinal chemistry [J Enzyme Inhib Med Chem] 2019 Dec; Vol. 34 (1), pp. 1368-1372.Publisher: Taylor & Francis Country of Publication: England NLM ID: 101150203 Publication Model: Print Cited Medium: Internet ISSN: 1475-6374

Record details

×
Academic Journal

Discovery of a novel potent GPR40 full agonist.

  • Authors : Meegalla SK; CVM Discovery, Janssen Research & Developmen, LLC, Welsh and McKean Roads, Spring House, PA 19477-0776, USA.; Huang H

Subjects: Hypoglycemic Agents/Hypoglycemic Agents/Hypoglycemic Agents/*pharmacology ; Pyrazines/Pyrazines/Pyrazines/*pharmacology ; Receptors, G-Protein-Coupled/Receptors, G-Protein-Coupled/Receptors, G-Protein-Coupled/*agonists

  • Source: Bioorganic & medicinal chemistry letters [Bioorg Med Chem Lett] 2018 Feb 15; Vol. 28 (4), pp. 720-726. Date of Electronic Publication: 2018 Jan 12.Publisher: Elsevier Science Ltd Country of Publication: England NLM ID: 9107377 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

×
Academic Journal

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes.

Subjects: Cardiovascular Diseases/Cardiovascular Diseases/Cardiovascular Diseases/*complications ; Diabetes Mellitus, Type 2/Diabetes Mellitus, Type 2/Diabetes Mellitus, Type 2/*drug therapy ; Hypoglycemic Agents/Hypoglycemic Agents/Hypoglycemic Agents/*adverse effects

  • Source: The New England journal of medicine [N Engl J Med] 2015 Jul 16; Vol. 373 (3), pp. 232-42. Date of Electronic Publication: 2015 Jun 08.Publisher: Massachusetts Medical Society Country of Publication: United States NLM ID: 0255562 Publication Model: Print-Electronic Cited Medium:

Record details

×
Academic Journal

Synthesis and hypoglycemic activity of substituted 8-(1-piperazinyl)imidazo[1,2-a]pyrazines.

  • Authors : Meurer LC; Merck Sharp and Dohme Research Laboratories, Rahway, New Jersey 07065.; Tolman RL

Subjects: Adrenergic alpha-Antagonists/Adrenergic alpha-Antagonists/Adrenergic alpha-Antagonists/*chemical synthesis ; Hypoglycemic Agents/Hypoglycemic Agents/Hypoglycemic Agents/*chemical synthesis ; Piperazines/Piperazines/Piperazines/*chemical synthesis

  • Source: Journal of medicinal chemistry [J Med Chem] 1992 Oct 16; Vol. 35 (21), pp. 3845-57.Publisher: American Chemical Society Country of Publication: United States NLM ID: 9716531 Publication Model: Print Cited Medium: Print ISSN:

Record details

×
Academic Journal

Effects of tetramethylpyrazine phosphate on pancreatic islet microcirculation in SD rats.

  • Authors : Xu X; Department of Endocrinology and Metabolism, Affiliated Zhongshan Hospital of Fudan University, NO. 180, Feng Lin Road, Xu Hui District, Shanghai, 200032, People's Republic of China.; Institute of Chronic Metabolic Diseases of Fudan University, NO. 130, Dong An Road, Xu Hui District, Shanghai, 200032, People's Republic of China.

Subjects: Glucose/Glucose/Glucose/*pharmacology ; Hypoglycemic Agents/Hypoglycemic Agents/Hypoglycemic Agents/*pharmacology ; Insulin/Insulin/Insulin/*metabolism

  • Source: Journal of endocrinological investigation [J Endocrinol Invest] 2018 Apr; Vol. 41 (4), pp. 411-419. Date of Electronic Publication: 2017 Sep 16.Publisher: Springer Country of Publication: Italy NLM ID: 7806594 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1720-8386

Record details

×
Academic Journal

Drug utilization, safety, and effectiveness of exenatide, sitagliptin, and vildagliptin for type 2 diabetes in the real world: data from the Italian AIFA Anti-diabetics Monitoring Registry.

Subjects: Adamantane/Adamantane/Adamantane/*analogs & derivatives ; Diabetes Mellitus, Type 2/Diabetes Mellitus, Type 2/Diabetes Mellitus, Type 2/*drug therapy ; Hypoglycemic Agents/Hypoglycemic Agents/Hypoglycemic Agents/*therapeutic use

  • Source: Nutrition, metabolism, and cardiovascular diseases : NMCD [Nutr Metab Cardiovasc Dis] 2014 Dec; Vol. 24 (12), pp. 1346-53. Date of Electronic Publication: 2014 Oct 06.Publisher: Elsevier Country of Publication: Netherlands NLM ID: 9111474 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

×
Academic Journal

Understanding the molecular dynamics of type-2 diabetes drug target DPP-4 and its interaction with Sitagliptin and inhibitor Diprotin-A.

  • Authors : Chakraborty C; School of Computer and Information Sciences, Galgotias University, Greater Noida, India.; Hsu MJ

Subjects: Molecular Dynamics Simulation*; Diabetes Mellitus, Type 2/Diabetes Mellitus, Type 2/Diabetes Mellitus, Type 2/*drug therapy ; Dipeptidyl Peptidase 4/Dipeptidyl Peptidase 4/Dipeptidyl Peptidase 4/*metabolism

  • Source: Cell biochemistry and biophysics [Cell Biochem Biophys] 2014 Nov; Vol. 70 (2), pp. 907-22.Publisher: Humana Press Country of Publication: United States NLM ID: 9701934 Publication Model: Print Cited Medium: Internet ISSN: 1559-0283

Record details

×
Review

Maculopapular-type drug eruption caused by sitagliptin phosphate hydrate: a case report and mini-review of the published work.

  • Authors : Nakai N; Department of Dermatology, Kyoto Prefectural University of Medicine Graduate School of Medical Science, Kyoto, Japan.; Katoh N

Subjects: Diabetes Mellitus, Type 2/Diabetes Mellitus, Type 2/Diabetes Mellitus, Type 2/*drug therapy ; Drug Eruptions/Drug Eruptions/Drug Eruptions/*prevention & control ; Hypersensitivity, Delayed/Hypersensitivity, Delayed/Hypersensitivity, Delayed/*prevention & control

  • Source: Allergology international : official journal of the Japanese Society of Allergology [Allergol Int] 2014 Sep; Vol. 63 (3), pp. 489-91.Publisher: Elsevier Country of Publication: England NLM ID: 9616296 Publication Model: Print Cited Medium: Internet ISSN: 1440-1592 (Electronic)

Record details

×
Academic Journal

Lansoprazole enhances the antidiabetic effect of sitagliptin in mice with diet-induced obesity and healthy human subjects.

  • Authors : Hao S; Department of Pharmacy and Equipment, No. 371 Hospital of PLA, Xin'xiang, China.; Sun J

Subjects: Hypoglycemic Agents/Hypoglycemic Agents/Hypoglycemic Agents/*pharmacology ; Hypoglycemic Agents/Hypoglycemic Agents/Hypoglycemic Agents/*therapeutic use ; Lansoprazole/Lansoprazole/Lansoprazole/*pharmacology

  • Source: The Journal of pharmacy and pharmacology [J Pharm Pharmacol] 2014 Aug; Vol. 66 (8), pp. 1133-9. Date of Electronic Publication: 2014 Mar 13.Publisher: Oxford University Press Country of Publication: England NLM ID: 0376363 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

×
Academic Journal

The efficacy and safety of imeglimin as add-on therapy in patients with type 2 diabetes inadequately controlled with sitagliptin monotherapy.

Subjects: Diabetes Mellitus, Type 2/Diabetes Mellitus, Type 2/Diabetes Mellitus, Type 2/*drug therapy ; Hypoglycemic Agents/Hypoglycemic Agents/Hypoglycemic Agents/*therapeutic use ; Pyrazines/Pyrazines/Pyrazines/*therapeutic use

  • Source: Diabetes care [Diabetes Care] 2014 Jul; Vol. 37 (7), pp. 1924-30. Date of Electronic Publication: 2014 Apr 10.Publisher: American Diabetes Association Country of Publication: United States NLM ID: 7805975 Publication Model: Print-Electronic Cited Medium:

Record details

×
  • 1-10 of  477 results for ""PYRAZINES""